Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2023 Earnings Conference Call February 27, 2024 4:30 PM ET

Company Participants

Matt Scalo - Senior Vice President, Investor Relations

Paul Diaz - President & Chief Executive Officer

Mark Verratti - Chief Commercial Officer

Sam Raha - Chief Operating Officer

Scott Leffler - Chief Financial Officer

Conference Call Participants

Andrew Cooper - Raymond James

Prashant Kota - Goldman Sachs

Jack Meehan - Nephron Research

David Westenberg - Piper Sandler

Mason Carrico - Stephens

Kyle Boucher - TD Cowen

Brandon Kramer - Guggenheim Securities

Puneet Souda - Leerink Partners

John Kim - Bank of America

Operator

Good day and welcome to the Myriad Genetics Fourth Quarter 2023 Financial Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. [Operator Instructions] As a reminder this call is being recorded.

I would now like to turn the call over to Matt Scalo. You may begin.

Matt Scalo

All right. Thanks Michelle and good afternoon and welcome to the Myriad Genetics fourth quarter and full year 2023 earnings call. During the call, we will review the financial results we released today and afterwards, we will host a question-and-answer session. Our quarterly earnings release was issued this afternoon on Form 8-K and can be found on our website at investor.myriad.com.

I'm Matt Scalo Senior Vice President of Investor Relations and on the call today are Paul Diaz, our President and Chief Executive Officer; Scott Leffler, our Chief Financial Officer; Sam Raha, our Chief Operating Officer; and Mark Verratti, our Chief Commercial Officer.

This call can be heard live via webcast at investor.myriad.com and a recording will be archived in the Investors section of our website along with this slide presentation.

Please note that some of the information presented today contains projections or other forward-looking statements regarding future events or the future financial performance of the company.

These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations for a variety of reasons.

We refer you to the documents the company files from time-to-time with the Securities and Exchange Commission, specifically the company's annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in our projections or forward-looking statements.